Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1127283

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to encourage fairer pricing by pharmaceutical companies for drugs supplied to the NHS.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	255651
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The 2019 Voluntary Scheme for Branded Medicines Pricing and Access, and the statutory scheme for branded medicines pricing, work together to control the cost of branded medicines to the National Health Service and ensure it stays within affordable limits.</p><p> </p><p>The 2019 Voluntary Scheme began on 1 January 2019 and will run for five years until the end of 2023. The Voluntary Scheme aims to provide stability and predictability for all parties in terms of the United Kingdom’s branded medicines expenditure and the medicines pricing and access environment for the period 2019 to 2023. It also aims to achieve a balance between patient access, affordability and supporting the development of innovative new medicines, including support for small companies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:30:06 answering member 4455 label Biography information for Seema Kennedy
tabling member	308 label Biography information for Mr Jim Cunningham

1127317

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Bowel Cancer: Young People
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to reduce the number of young people developing bowel cancer.
tabling member constituency	Coventry South
tabling member printed	Mr Jim Cunningham
uin	255652
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Obesity and poor diet are risk factors for bowel cancer in young people.</p><p>The second chapter of the world-leading childhood obesity plan was published in June 2018. This builds on the real progress made since the publication of chapter one in 2016, particularly in reformulation of the products our children eat and drink most. In chapter two we have set a bold ambition to halve childhood obesity by 2030 and significantly reduce the gap in obesity between children from the most and least deprived areas by 2030.</p><p>Many of the measures in both chapters of the plan will have an impact on tackling obesity across all age groups. These include the soft drinks industry levy, sugar reduction and wider calorie reformulation programme, restricting promotions and calorie labelling in restaurants which will improve our eating habits and reduce the amount of sugar we consume.</p><p>‘Childhood obesity: a plan for action, chapter 2’ is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2" target="_blank">www.gov.uk/government/publications/childhood-obesity-a-plan-for-action-chapter-2</a></p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:24:08 answering member 4455 label Biography information for Seema Kennedy
tabling member	308 label Biography information for Mr Jim Cunningham

1127327

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diffuse Intrinsic Pontine Glioma
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of access to NHS support for sufferers of diffuse intrinsic pontine glioma.
tabling member constituency	Sheffield, Brightside and Hillsborough
tabling member printed	Gill Furniss
uin	255692
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>No specific assessment has been made by the Department at this time.</p><p>Care for children with Diffuse Intrinsic Pontine Glioma (DIPG) is co-ordinated and provided by Children’s Cancer Principal Treatment Centres (PTCs) working in conjunction with Paediatric Oncology Shared Care Units. Children’s Cancer PTCs are responsible for planning and delivering treatment for children with DIPG as well as ensuring these children can access wider support services such as psychology services, specialist play services and other therapies.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:25:19 answering member 4455 label Biography information for Seema Kennedy
tabling member	4571 label Biography information for Gill Furniss

1127334

registered interest
date	17/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Isotretinoin: Side Effects
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential health risks and psychiatric side-effects of the drug Roaccutane.
tabling member constituency	Newcastle-under-Lyme
tabling member printed	Paul Farrelly
uin	255661
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>As with all medicines in the United Kingdom, the Medicines and Healthcare products Regulatory Agency continuously monitors the safety of isotretinoin-containing medicines. This includes reports of suspected adverse drug reactions submitted by healthcare professionals, patients and carers through the Yellow Card scheme, as well as published and unpublished data. As new evidence on safety emerges it is carefully evaluated and, where appropriate, product information is updated and advice for prescribers and patients is issued.</p><p>Specific assessments of possible psychiatric side effects associated with isotretinoin were considered by an Expert Working Group of the Commission on Human Medicines in 2005 and 2014. In addition, the risk of neuropsychiatric disorders was evaluated in a European review which was completed in 2018. This review concluded that the warnings in the product information for medicines containing isotretinoin regarding possible psychiatric adverse effects reflected what was known.</p><p>Since 1998, warnings regarding the possible risk of developing depression and other psychiatric side effects have been included in the product information for Roaccutane and the generic versions of isotretinoin (the Summary of Product Characteristics for healthcare professionals and the patient information leaflet). The product information for isotretinoin warns that treatment may be associated with possible psychiatric side effects, that particular care needs to be taken in patients with a history of depression; and that all patients on isotretinoin should be monitored for signs of depression and referred for appropriate treatment if necessary. It also states that stopping isotretinoin may not lead to improvement and therefore further psychiatric or psychological evaluation may be necessary.</p> answering member constituency Thurrock answering member printed Jackie Doyle-Price question first answered 22/05/2019 16:42:43 answering member 4065 label Biography information for Dame Jackie Doyle-Price
tabling member	1436 label Biography information for Paul Farrelly

1127289

registered interest
date	16/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Drugs: Prices
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the affordability of medicines as a result of the redrafted WHO resolution entitled, Improving the transparency of markets for medicines, vaccines and other health-related technologies proposed by Italy on 29 April 2019.
tabling member constituency	Liverpool, Walton
tabling member printed	Dan Carden
uin	255695
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The United Kingdom has a long-established and globally-recognised track record of assessing the price of new, innovative medicines by their clinical benefit and value, rather than by their development costs or international reference prices.</p><p>The UK will engage constructively with the talks at the World Health Assembly to achieve the best outcome for people here and globally, including in low and middle income countries. Pricing arrangements are the responsibility of Member States and are highly context specific, but the Department supports information sharing and mutual learning initiatives, where appropriate, in seeking to improve value for money for country procurement budgets.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 22/05/2019 14:32:11 answering member 4455 label Biography information for Seema Kennedy
tabling member	4651 label Biography information for Dan Carden

1125504

registered interest
date	08/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pneumococcal Diseases: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what assessment they have made of the recommendations by the Joint Committee on Vaccination and Immunisation to reduce the infant pneumococcal vaccination schedule from three doses to two.
tabling member printed	Baroness Masham of Ilton
uin	HL15599
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15600 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
tabling member	1850 label Biography information for Baroness Masham of Ilton

1125505

registered interest
date	08/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Pneumococcal Diseases: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what analyses they have conducted of the risks and benefits of reducing the infant pneumococcal vaccination schedule from 2+1 to 1+1; and whether they will publish the results any such analyses.
tabling member printed	Baroness Masham of Ilton
uin	HL15600
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) provides independent expert advice on the United Kingdom’s immunisation programme. As an independent committee, it is well placed to ensure the latest and most appropriate evidence has been considered on potential changes to scheduling within the vaccine programme. It bases its advice on review of a wide range of scientific and other evidence, including from the published literature, commissioned studies such as independent analyses of vaccine effectiveness and cost effectiveness.</p><p>The JCVI advised that a two-dose schedule for the infant pneumococcal conjugate vaccine (PCV) Prevenar13 is appropriate for the UK. Its advice takes into account the public health aspects of any potential change to the vaccination schedule, such as the potential impact on cases of infectious disease. The JCVI consulted relevant stakeholders on its proposed advice, between January and April 2018, to ensure that its advice reflects all the evidence.</p><p>The JCVI’s advice on the infant pneumococcal programme was given full consideration, including the potential public health implications, before a decision was made to implement it. The UK frequently adopts innovative immunisation schedules and we regularly change the vaccine schedule following the advice of our independent expert committee, as we are doing in this case.</p><p>The decision is based on the excellent effectiveness of the vaccine and years of high uptake, which has helped to provide protection to the rest of the population and has successfully controlled many types of pneumococcal disease in this country. The evidence shows that two doses will sustain the excellent results we have already seen. We are confident that the world-class disease surveillance system we have in this country means our expert committee can closely monitor the impact of this change. This is set out in the JCVI’s minutes which are attached.</p> answering member printed Baroness Blackwood of North Oxford grouped question UIN HL15599 question first answered 22/05/2019 14:50:14 answering member 4019 label Biography information for Baroness Blackwood of North Oxford attachment 1 file name JCVI Minute 2015 10 Attached to HL16000 and 15999.pdf title JCVI Minute 2015
tabling member	1850 label Biography information for Baroness Masham of Ilton

1125506

registered interest
date	08/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	HIV Infection: Vaccination
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what steps they are taking to improve vaccination coverage for people living with HIV.
tabling member printed	Baroness Masham of Ilton
uin	HL15601
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>Public Health England, in partnership with NHS England and the Department, is taking steps to improve vaccination coverage in England, including for people living with HIV.</p><p>These steps include initiatives to improve access to the immunisation programme; communication with the public; data to identify underserved individuals and populations; and training for healthcare professionals, changes to vaccination eligibility criteria; launching disease elimination strategies; running targeted social media campaigns; providing information leaflets in multiple languages and running e-learning programme for healthcare practitioners.</p><p>Certain vaccines are delivered through sexual health services that particularly benefit people living with HIV. This includes vaccines for hepatitis A, hepatitis B and human papillomavirus. People living with HIV are in the influenza risk groups and are invited for the flu vaccine on an annual basis.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:50:46 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1850 label Biography information for Baroness Masham of Ilton

1125517

registered interest
date	08/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Migrant Workers
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty's Government what plans they have, if any, to increase the number of NHS staff recruited from EU member states after Brexit.
tabling member printed	Lord Taylor of Warwick
uin	HL15612
answer	answer is ministerial correction date of answer 22/05/2019 answer text <p>The Government recognises the need to be able to recruit effectively from abroad and the Immigration White Paper, <em>The UK’s future skills-based immigration system</em>, published in December 2018, sets out the foundation for a single immigration system, where it is workers’ skills that matter, not where they come from. This system will streamline the high-skilled visa route, by removing the Resident Labour Market Test and the Tier 2 Visa Cap. The Home Office is undertaking a programme of engagement to discuss the proposed measures with colleagues across Government and industry, to develop a future immigration system that works for the whole of the United Kingdom.</p><p>The Government wants to support the National Health Service in expanding international recruitment more widely, as this clearly has a role to play to meeting staffing shortages, especially in the short term. Recruitment of doctors and nurses is the responsibility of individual NHS organisations, a number of which do actively recruit from overseas, including from countries in the European Union. However, we also recognise the need to boost our domestic workforce as well. The NHS Long Term Plan sets out a vital strategic framework to ensure that, over the next 10 years, the NHS will have the staff it needs so that nurses and doctors are working in a supportive culture that allows them to provide the expert compassionate care they are committed to providing. Details of this will be explored more fully in the forthcoming Interim NHS People Plan.</p><p>The Government has taken steps to ensure that EU citizens can continue to come and work in the NHS once we have left the EU. In March 2019, we put in place legislation that ensures the continued recognition of qualifications from EU countries by all professional regulators covering the health and social care sectors. This means that EU citizens will continue to be able to come and practice in the UK once we have left the EU, even if we leave without a deal.</p> answering member printed Baroness Blackwood of North Oxford question first answered 22/05/2019 14:54:38 answering member 4019 label Biography information for Baroness Blackwood of North Oxford
tabling member	1796 label Biography information for Lord Taylor of Warwick